Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.
T. Traina,K. Miller,17 Authors,J. Cortés
2018 · DOI: 10.1200/JCO.2016.71.3495
Journal of Clinical Oncology · 397 Citations
TLDR
This phase II study evaluated the antitumor activity and safety of enzalutamide in patients with locally advanced or metastatic AR-positive TNBC and demonstrated clinical activity and was well tolerated in Patients with advanced AR- positive TNBC.